Brief: Galecto Announces Topline Results From Phase 2B Galactic-1 Trial Of Gb0139 For The Treatment Of Idiopathic Pulmonary Fibrosis

Damora Therapeutics

15/08/2023 12:31

Galecto Inc  GLTO.O :
    * GALECTO ANNOUNCES TOPLINE RESULTS FROM PHASE 2B GALACTIC-1
TRIAL
OF GB0139 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    * GALECTO INC - GALACTIC-1 TRIAL DID NOT MEET ITS PRIMARY
ENDPOINT
OF CHANGE FROM BASELINE IN RATE OF DECLINE IN FORCED VITAL
CAPACITY
    * GALECTO INC: PLANS TO DISCONTINUE DEVELOPMENT OF GB0139
    * GALECTO INC: WILL FOCUS ON DEVELOPMENT OPPORTUNITIES FOR
TREATMENT OF SEVERE LIVER DISEASES
    * GALECTO INC - CURRENTLY EVALUATING RESOURCE ALLOCATION
WITH GOAL
OF EXTENDING OUR CASH RUNWAY INTO 2025
    * GALECTO INC - GALECTO PLANS TO COMMUNICATE RESULTS OF
GALACTIC-1
TRIAL AT AN UPCOMING MEDICAL CONFERENCE
    * GALECTO INC: GOING FORWARD, WE ARE "EAGER TO EXPAND" OUR
FOCUS
ON ADVANCING OUR PIPELINE OF OUR ORALLY ADMINISTERED COMPOUNDS,
GB1211 AND GB2064
    * GALECTO INC - GALECTO INTENDS TO WORK IN CLOSE
COLLABORATION
WITH EXTERNAL EXPERTS TO ANALYZE RESULTS OBSERVED IN PLACEBO ARM
OF GALACTIC-1 TRIAL

Source text for Eikon:  ID:nGNX7X0hGq 
Further company coverage:  GLTO.O